NA
Publicaties op Oncologisch.com
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant...
FDA-goedkeuring van capivasertib plus fulvestrant bij mammacarcinoom
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.
FDA-goedkeuring van cabozantinib bij gedifferentieerd schildkliercarcinoom